Skip to content
Catalyst brief · Phase 3 readout · 26 days

Tobevibart: Tobevibart in Viral Hepatitis

Vir Biotechnology, Inc. · $VIR · built 19 Nov 2026 from 16 sourced facts · open on the radar

Analyst desk

Five AI analysts read the facts below. Each sentence shows the facts it rests on.

Trial design

  • The trial's main goal is to measure HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24, which is a specific and quantifiable outcome, making the results more convincing. F1 F3
  • The trial is open label, meaning there is no blinding, which may introduce bias and affect the convincingness of the results. F1 F4
  • The trial is randomised, which helps to reduce bias and ensures that the results are more reliable and convincing. F1 F5
  • The trial plans to enrol 150 patients, which is a relatively small sample size, and has 2 study arms, which may impact the convincingness of the results. F2 F7

Base rates

  • Historically, 64.0% of Phase 3 programmes in infectious disease moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F12
  • The DataCutoff timing model estimates this trial finishes about 4 months after its registry date, and up to 10 months in slower cases. F11
  • On average, VIR's past trial-result days saw an absolute share move of 8.2%, but this is just a historical record and not a forecast for this event. F13

Filings

  • The company has a cash position of $455M and a runway of about 39 months, which is beyond the estimated primary completion date of the trial. F14 F15
  • There have been no open-market insider purchases or unplanned sales reported in the last 90 days. F16
  • The primary completion date of the trial is estimated to be around Dec 2026, which is 26 days from the current date. F9
  • Historical data shows that 64.0% of Phase 3 programmes in infectious disease moved on to a regulatory filing, and the company has had an average absolute share move of 8.2% on past trial-result days. F12 F13

The case for

  • The trial has a clear and quantifiable main goal, and its randomised design helps to reduce bias, making the results more reliable and convincing. F1 F3 F5

The case against

  • The trial's open-label design may introduce bias and affect the convincingness of the results, potentially leading to a failed trial or delayed reporting. F1 F4
  • The trial's primary completion date is estimated to be around Dec 2026, but the DataCutoff timing model estimates that the trial may finish later than expected, up to 10 months after its registry date, which could lead to a delayed report. F9 F11

Open questions

  • Will Tobevibart meet its main goal of HDV RNA < LLOQ at Week 24?
  • How will the open-label design impact the convincingness of the trial results?
  • Will the trial's results lead to a regulatory filing given the historical 64.0% success rate in infectious disease?

6 AI sentences were removed by the fact check.

The facts

The trial

  • F1Tobevibart is a Phase 3 trial of Tobevibart in Viral Hepatitis, sponsored by Vir Biotechnology, Inc. (VIR). source ↗
  • F2The trial plans to enrol 150 patients. source ↗

What counts as success

  • F3Main goal as written in the registry: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24. source ↗
  • F4Blinding: open label (no blinding). source ↗
  • F5Allocation: randomised. source ↗
  • F6The main goal is measured over: Week 24. source ↗
  • F7Number of study arms: 2. source ↗

When

  • F9The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
  • F10The date has not moved later since the first registry version. source ↗
  • F11The DataCutoff timing model estimates this trial finishes about 4 months after its registry date, and up to 10 months in the slower quarter of cases. source ↗

Recruitment

Base rates

  • F12Historically 64.0% of Phase 3 programmes in infectious disease (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
  • F13VIR has had 2 past trial-result days on record, with an average absolute share move of 8.2%. source ↗

Money, insiders and FDA

  • F14VIR reported $455M in cash and short-term investments as of 30 Sep 2026 (10-Q). source ↗
  • F15At the last 12 months' rate of spending (about $12M a month) that cash lasts about 39 months, to around Dec 2029, which is after the registry's primary completion date. source ↗
  • F16No open-market insider purchases or unplanned sales were reported in the last 90 days. source ↗

How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.